Skip to main content
Premium Trial:

Request an Annual Quote

Pacific Edge Signs on PPO FedMed for Cxbladder Access

NEW YORK (GenomeWeb News) – New Zealand cancer diagnostics firm Pacific Edge said today that its US subsidiary has finalized a deal with preferred provider organization FedMed to offer Pacific Edge's bladder cancer test in the US.

The deal provides contracted insurance carriers, third-party administrators, health and welfare funds, and self-insured health plans access to Pacific Edge's gene expression test called Cxbladder. More than 40 million Americans have access to FedMed's network of more than 550,000 physicians, 4,000 hospitals, and 60,000 ancillary care providers, Pacific Edge said.

The deal was struck between its US subsidiary, Pacific Edge Diagnostics USA and FedMed.

Cxbladder is urine-based and comprises five biomarkers. It identifies patients with changes in gene expression and helps rule out cancer in patients with normal gene expression.

The test will be performed in Pacific Edge Diagnostics USA's CLIA-certified laboratory in Hershey, Pa.

"The building blocks are in place, sales people are active in the market, and Pacific Edge remains confident of reaching its target of revenues of $100 million from Cxbladder sales in the USA within five trading years," Pacific Edge CEO David Darling said in a statement.